Histone deacetylase inhibitors (HDACIs) may overcome endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. We tested whether 18F-fluoroestradiol PET imaging would elucidate the pharmacodynamics of combination HDACIs and endocrine therapy. Methods: Patients with ER+/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer with prior clinical benefit from endocrine therapy but later progression on aromatase inhibitor (AI) therapy were given vorinostat (400 mg daily) sequentially or simultaneously with AI. 18F-fluoroestradiol PET and 18F-FDG PET scans were performed at baseline, week 2, and week 8. Results: Eight patients were treated sequentially, and then 15 simultaneously. Eight patients had stable disease at week 8, and 6 of these 8 patients had more than 6 mo of stable disease. Higher baseline 18F-fluoroestradiol uptake was associated with longer progression-free survival. 18F-fluoroestradiol uptake did not systematically increase with vorinostat exposure, indicating no change in regional ER estradiol binding, and 18F-FDG uptake did not show a significant decrease, as would have been expected with tumor regression. Conclusion: Simultaneous HDACIs and AI dosing in patients with cancer resistant to AI alone showed clinical benefit (6 or more months without progression) in 4 of 10 evaluable patients. Higher 18F-fluoroestradiol PET uptake identified patients likely to benefit from combination therapy, but vorinostat did not change ER expression at the level of detection of 18F-fluoroestradiol PET.

Cancer Imaging Program National Cancer Institute Bethesda Maryland

Clinical Research and Public Health Sciences Division Fred Hutchinson Cancer Research Center Seattle Washington

Department of Biostatistics University of Pittsburgh Pittsburgh Pennsylvania

Department of Diagnostic Radiology Oregon Health and Science University Portland Oregon; and

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Department of Radiology University of Pennsylvania Philadelphia Pennsylvania

Division of Medical Oncology University of Washington Seattle Cancer Care Alliance Seattle Washington

Zobrazit více v PubMed

Carlson RW, Anderson BO, Burstein HJ, et al. . Invasive breast cancer. J Natl Compr Canc Netw. 2007;5:246–312. PubMed

Hanamura T, Hayashi SI. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications. Breast Cancer. 2018;25:379–391. PubMed

NCCN guideline update: breast cancer version 1.2004. J Natl Compr Canc Netw. 2004;2:183–184. PubMed

Turner NC, Ro J, Andre F, et al. . Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219. PubMed

Piccart M, Hortobagyi GN, Campone M, et al. . Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25:2357–2362. PubMed PMC

André F, Ciruelos E, Rubovszky G, et al. . Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929–1940. PubMed

Raha P, Thomas S, Thurn KT, Park J, Munster PN. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015;17:26. PubMed PMC

Fan J, Yin WJ, Lu JS, et al. . ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol. 2008;134:883–890. PubMed

Giacinti L, Claudio PP, Lopez M, Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist. 2006;11:1–8. PubMed

Jang ER, Lim SJ, Lee ES, et al. . The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene. 2004;23:1724–1736. PubMed

Lee YJ, Won AJ, Lee J, et al. . Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci. 2012;9:881–893. PubMed PMC

Thomas S, Thurn KT, Bicaku E, Marchion DC, Munster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011;130:437–447. PubMed PMC

Connolly R, Stearns V. Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia. 2012;17:191–204. PubMed PMC

Krusche CA, Wulfing P, Kersting C, et al. . Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005;90:15–23. PubMed

Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 2011;71:1893–1903. PubMed PMC

Yardley DA, Ismail-Khan RR, Melichar B, et al. . Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31:2128–2135. PubMed PMC

Munster PN, Thurn KT, Thomas S, et al. . A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104:1828–1835. PubMed PMC

Yeruva SLH, Zhao F, Miller KD, et al. . E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer. 2018;4:1. PubMed PMC

Peterson LM, Mankoff DA, Lawton T, et al. . Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med. 2008;49:367–374. PubMed

Koleva-Kolarova RG, Greuter MJ, van Kruchten M, et al. . The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients. Br J Cancer. 2015;112:1617–1625. PubMed PMC

Gong C, Yang Z, Sun Y, et al. . A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. Sci Rep. 2017;7:6584. PubMed PMC

He S, Wang M, Yang Z, et al. . Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET imaging probes for early prediction and monitoring of response to endocrine therapy in a mouse xenograft model of ER-positive breast cancer. PLoS One. 2016;11:e0159916. PubMed PMC

Kurland BF, Peterson LM, Lee JH, et al. . Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clin Cancer Res. 2017;23:407–415. PubMed PMC

Linden HM, Kurland BF, Peterson LM, et al. . Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011;17:4799–4805. PubMed PMC

Connolly RM, Leal JP, Goetz MP, et al. . TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med. 2015;56:31–37. PubMed PMC

Kurland BF, Gadi VK, Specht JM, et al. . Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res. 2012;2:34. PubMed PMC

Ulaner GA, Eaton A, Morris PG, et al. . Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med. 2013;2:725–733. PubMed PMC

Zhang J, Jia Z, Zhang Y, et al. . The maximum standardized uptake value of 18F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer. BMC Cancer. 2013;13:42. PubMed PMC

Peterson LM, O’Sullivan J, Wu QV, et al. . Prospective study of serial 18F-FDG PET and 18F-fluoride PET to predict time to skeletal-related events, time to progression, and survival in patients with bone-dominant metastatic breast cancer. J Nucl Med. 2018;59:1823–1830. PubMed PMC

Kelly WK, O’Connor OA, Krug LM, et al. . Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923–3931. PubMed PMC

Luu TH, Morgan RJ, Leong L, et al. . A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008;14:7138–7142. PubMed PMC

Linden HM, Stekhova SA, Link JM, et al. . Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793–2799. PubMed

Research on Obesity: A Report of the DHSS/MRC Group. Her Majesty’s Stationary Office; 1976:94.

Byrd DW, Doot RK, Allberg KC, et al. . Evaluation of cross-calibrated 68Ge/68Ga phantoms for assessing PET/CT measurement bias in oncology imaging for single- and multicenter trials. Tomography. 2016;2:353–360. PubMed PMC

Kurland BF, Peterson LM, Shields AT, et al. . Test-retest reproducibility of 18F-FDG PET/CT uptake in cancer patients within a qualified and calibrated local network. J Nucl Med. 2019;60:608–614. PubMed PMC

Venema CM, Apollonio G, Hospers GA, et al. . Recommendations and technical aspects of 16α-[18F]fluoro-17β-estradiol PET to image the estrogen receptor in vivo: the Groningen experience. Clin Nucl Med. 2016;41:844–851. PubMed

18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer